Skip to main content

Table 3 Eradication rates per protocol in peptic ulcer disease and dyspepsia in groups of active and placebo probiotic

From: Association of a probiotic to a Helicobacter pylorieradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study

  Peptic ulcer (CI 95%) Dyspepsia (CI 95%)
Active probiotic 95.8% (87-100%) 84.0% (74-100%)
Placebo probiotic 85.7% (69-100%) 84.6% (70-99%)
Pearson Chi-Square p = 0.23 p = 0.95